Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (191-200 of 293) with videos related to

Pageof 30
Sort By:
Rheumatology (Oxford, England)|July 18, 2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-upRoy Fleischmann, Mark C Genovese, Yong Lin, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Journal of Autoimmunity|January 15, 2023
Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patientsAlexander Ten Hagen, Sandra Hermann, Elisa Habermann, et al.
Annals of the Rheumatic Diseases|March 12, 2017
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisJackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, et al.
BMC Musculoskeletal Disorders|August 1, 2015
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Annals of the Rheumatic Diseases|December 14, 2012
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisGerd R Burmester, Michael E Weinblatt, Iain B McInnes, et al.
RMD Open|January 3, 2023
Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participationMaarten H P Butink, Casper Webers, Suzanne M M Verstappen, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritisJacqueline Detert, René Dziurla, Paula Hoff, et al.
Pageof 30

Showing results (191-200 of 293) with videos related to

Sort By:
Pageof 30
Rheumatology (Oxford, England)|July 18, 2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-upRoy Fleischmann, Mark C Genovese, Yong Lin, et al.
Blood|November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myelomaChristian Jakob, Karl Egerer, Peter Liebisch, et al.
Journal of Autoimmunity|January 15, 2023
Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patientsAlexander Ten Hagen, Sandra Hermann, Elisa Habermann, et al.
Annals of the Rheumatic Diseases|March 12, 2017
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritisJackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Annals of the Rheumatic Diseases|February 9, 2020
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritisAndreas Kerschbaumer, Alexandre Sepriano, Josef S Smolen, et al.
BMC Musculoskeletal Disorders|August 1, 2015
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Annals of the Rheumatic Diseases|December 14, 2012
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisGerd R Burmester, Michael E Weinblatt, Iain B McInnes, et al.
RMD Open|January 3, 2023
Non-pharmacological interventions to promote work participation in people with rheumatic and musculoskeletal diseases: a systematic review and meta-analysis from the EULAR taskforce on healthy and sustainable work participationMaarten H P Butink, Casper Webers, Suzanne M M Verstappen, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritisJacqueline Detert, René Dziurla, Paula Hoff, et al.
Pageof 30